Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-4247
Sander, P; Springer, B; Prammananan, T; Sturmfels, A; Kappler, M; Pletschette, M; Böttger, E C (2002). Fitness cost of chromosomal drug resistance-conferring mutations. Antimicrobial Agents and Chemotherapy, 46(5):1204-1211.
To study the cost of chromosomal drug resistance mutations to bacteria, we investigated the fitness cost of mutations that confer resistance to different classes of antibiotics affecting bacterial protein synthesis (aminocyclitols, 2-deoxystreptamines, macrolides). We used a model system based on an in vitro competition assay with defined Mycobacterium smegmatis laboratory mutants; selected mutations were introduced by genetic techniques to address the possibility that compensatory mutations ameliorate the resistance cost. We found that the chromosomal drug resistance mutations studied often had only a small fitness cost; compensatory mutations were not involved in low-cost or no-cost resistance mutations. When drug resistance mutations found in clinical isolates were considered, selection of those mutations that have little or no fitness cost in the in vitro competition assay seems to occur. These results argue against expectations that link decreased levels of antibiotic consumption with the decline in the level of resistance.
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > Institute of Medical Microbiology|
|DDC:||570 Life sciences; biology|
610 Medicine & health
|Deposited On:||26 Mar 2009 13:38|
|Last Modified:||23 Nov 2012 14:15|
|Publisher:||American Society for Microbiology|
|Additional Information:||Copyright: American Society for Microbiology|
Scopus®. Citation Count: 93
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page